LondonCEO & Chairman, Axion Scientific Ltd.

Victor
Muraviev

For approximately a decade, I have worked on AGI and ASI alignment.

As CEO & Chairman, I have directed Axion Scientific since 2025.

I have worked in investments, particularly in equities and derivatives, since 2019, and have worked across performance pharmacology, biological adaptation, philosophy, and artificial intelligence.

Research, investments & writingme@victorm.co.uk

AI development
and alignment.

I have been bullish on artificial superintelligence since 2017 and have covered OpenAI and Neuralink since 2019. Before LLMs became the dominant approach to advancing AI, I expected ASI to be reached primarily through the digitisation of biology and placed particular weight on Neuralink and brain–computer interfaces.

Despite advances in large language technology, BCIs remain a matter of interest in AI development, usage and alignment, and their future importance is likely to increase substantially.

You can see my writings on AI alignment and development, including various architectures, including but not limited to LLMs, harnesses and more on my X profile: 0xVM7.

From Tesla & Semiconductors
to Nebius.

  1. 2019

    Started investing with TSLA and semiconductors.

  2. 2020

    Majority-TSLA portfolio from 2020.

  3. Interval

    Took time off for health.

  4. 2024

    Returned to active investing with a majority-NBIS portfolio.

Nebius Group NV / NBIS

A concentrated
AI-infrastructure
thesis.

Since returning to investments in 2024, I have centred my public-market strategy around Nebius Group using both equities and derivatives. The original thesis was that Arkady Volozh had moved from Yandex into a Western AI-infrastructure company while preserving much of the engineering base, experience and commercial network; Nebius also began with almost 2.5 billion USD in cash, little debt and a valuation below 10 billion USD.

The sanctions environment created an opportunity to buy into an elite AI-infrastructure company before the market repriced it.

I was one of the earliest public NBIS investors and commentators. I created the first dedicated NBIS subreddit and the first large NBIS-focused X account, @NBISStock (followed by Chief Business Officer & Co-founder Roman Chernin), covering earnings, financing, AI infrastructure, and positions in ClickHouse and Toloka, options positioning and valuation.

I was also one of the earliest commentators on DeepSeek R1 and Jevons paradox, successfully predicting the impacts of the model release on markets and the AI industry with this receiving over a million views on x.com.

Nebius subsequently reached a 52-week high of 299.86 USD per share, 19.90× my lowest documented entry. My ROI since returning to investments in 2024 exceeds 500% (6× gross).

Case Study on DeepSeek R1:

@0xVM7 on X
AI / investment analysisJanuary 2025

Inference economics and market expectations.

DeepSeek posts: over 1M combined viewsR1 release post on X
Read the analysis

I published my DeepSeek R1 analysis on 21 January 2025, six days before the market sell-off. My commentary subsequently received over 1M combined views on X. I anticipated the decline in prices across compute-exposed stocks, whilst acknowledging long-term bullishness due to factors such as Jevons paradox.

My release coverage addressed R1’s multi-stage RL/SFT pipeline, emergent reasoning behaviours and API pricing 20–30× below o1 at comparable performance. In discussion with Garry Tan on 25 January, I argued for long-term acceleration whilst also anticipating short-term crashes, pivots and fears of resource allocation changes regarding compute. That evening, I was setting new SLs on $NBIS, extending the downside view to $NVDA and the wider market despite the likelihood of a Jevons outcome.

Replying to my 25 January warning, Eddie Jones (fmr Bridgewater, running own book at the time) argued that R1 was not leading-edge and that compute requirements were increasing exponentially. Although I was of a similar opinion (as someone bullish on compute, AGI and further, since at least 2018), I had gauged market sentiment and my world model of market actors was indicating for me to anticipate negative price action from investors acting on inferior information or selling in anticipation of others doing so, whilst remaining bullish on the underlying long-term demand; “What we think ≠ what the rest of the market thinks.” When prices fell overnight on 27 January, I returned to the discussion with “Look at the overnight price action. Told you so…” and, replying to Eddie again, “I’m still long. I’m just accurately predicting the price action.”

Two days before industry leaders such as Satya Nadella (Microsoft chairman and CEO) publicly invoked Jevons paradox to explain why greater AI efficiency and accessibility would increase usage, I had already been applying that thesis around DeepSeek and correctly anticipated the short-term crash despite the long-term bullishness. As one of the earliest public NBIS investors and commentators, already heavily long since 2024, I had covered R1 six days before the sell-off and anticipated the adverse repricing of the same infrastructure on which I remained bullish long term. I published that assessment on 25 January; by the time of Nadella’s 27 January post, the overnight sell-off I had predicted was well underway. In my response to him, I linked the earlier warning. Before the US open (amidst market panic), I was already considering the extent of re-entry: “Waiting for reaction to open to see how much to re-enter with.”

Nvidia closed at $142.62 on Friday 24 January and $118.42 on Monday 27 January: a 16.97% decline. It closed at $128.99 on Tuesday, an 8.93% rebound from Monday. NBIS closed at $41.69 on 24 January and $26.08 on 27 January: a 37.44% decline. It closed at $30.09 on 28 January, a 15.38% rebound from Monday.

Unlike most of the bears and the bulls, I correctly identified that the trade would still be bullish, but that the market would likely react negatively because of inferior information being too prevalent amongst buyers and sellers. I then anticipated and predicted that negativity, re-entered at a lower price, and proceeded to benefit from massive increases in the price of Nebius Stock from that point on, which had 10X’d since the DeepSeek low.

24 Jan 2025$142.62NVIDIA filing
27 Jan 2025$118.42Pricing filing
28 Jan 2025$128.99Pricing filing

USD closing prices; percentage changes calculated close to close. These are stock-price moves, separate from the portfolio and option returns elsewhere on this page.

Dated source posts

Full text of the R1 release post and the January 25 market-risk note.

21 January 2025 / R1 release post
21 January 2025DeepSeek-R1 release post
DeepSeek-R1 just released. Fully open source & transparent with MIT license. Developed with reinforcement learning directly on the base model. 20-30x cheaper API at comparable performance to OAI’s o1. (USD) 0.14 / million input tokens (cache hit). 0.55 / million input tokens (cache miss). 2.19 / million output tokens. To simplify, R1 is like R1-Zero but with multi-stage training: Its pipeline: • Fine-tune base with CoT data points • RL stage similar to R1-Zero • SFT using ~600k data points from rejection sampling and supervised datasets (e.g., writing, self-cognition). • RL stage to optimise objectives: helpfulness, harm reduction, etc. Emergent properties like longer responses, reflection, and alternative exploration emerge as natural products during training without explicit programming. RL rewards focus: • Accuracy (e.g., unit test-based scoring for code). • Format (e.g., tags for reasoning separation and language consistency). No outcome/process RMs used (simpler).
25 January 2025 / Market-risk note
25 January 2025From the X archive
Setting new SLs with keeping this in mind (despite the likelihood of a Jevons paradox scenario RE: DeepSeek, markets could react very negatively in the short term). New SLs on $NBIS as DeepSeek could mean less demand for GPUs short term due to investor fear or anticipation of that. $NBIS rents out GPUs. $NBIS stock crash short term (maybe?). Long in the long term. You must understand that fear is an important part of decision-making in the market — sometimes, it makes irrational moves. This thinking also applies to $NVDA and, consequently, the whole market, too.

Reagents,
analysis and
filtration.

Following years of experience in the peptide industry, I became Chief Executive Officer and Chairman of Axion Scientific Ltd in 2025. I direct strategy and operations across Axion Reagents, Chemical Analysis and Filtration, and lead the company’s internal research division.

Company website

Axion Reagents

Research-use amino-acid reagents with third-party HPLC CoA and other quality testing.

Chemical Analysis

Handled reagent tests including TFA, pH, endotoxin, LC–MS, sterility and heavy-metals analysis.

Filtration

Filtration equipment and USP vials.

Response, limits
and adaptation.

Performance pharmacology

I built an education and consulting business around performance-enhancing compounds. I helped clients understand cutting-edge and extreme applications of AAS, rhGH, peptides, insulin and ancillaries, alongside bloodwork, training and recovery.

PEDs are, at best, the tertiary determinant of bodybuilding success. Genetics and energy availability make growth possible; training and pharmacology provide additional stimulus; and response to pharmacology is itself substantially genetic.

01 / rhGH → IGF-1

Plotting the upper end
of rhGH dose response.

I used extreme rhGH exposure to investigate endocrine and autocrine IGF-1 response. The results helped plot the upper end of the rhGH–IGF-1 curve and motivated a wider investigation of saturation, desensitisation, immunogenicity and why dose escalation ceases to produce a proportionate systemic response, illustrating its asymptotic nature in previously unexamined edge cases.

02 / Tendon adaptation / arm wrestling

Tendon adaptation,
mechanisms and applications.

My work covers tendon stiffness and high-tension, low-fatigue loading (Chris Beardsley); cross-sectional area, collagen synthesis and loading-bout refractoriness (Keith Baar); strain–time dose; and arm-wrestling-specific tendon targets, style-dependent loading and programming.

Philosophy.

Interests include

  • Mereology
  • Ontology
  • Epistemology
Document comparison

DocDifference.

A browser-local document comparison tool for text, PDF, Word and common document formats by Victor. Files remain in the browser rather than being uploaded for processing.

Open DocDifference

Other (much bigger) projects are currently private but planning to ship soon!

Education,
competition
and further study.

2017–2024

Kingston Grammar School

Senior Prize for Philosophy, Religion & Ethics; Junior Prize for Design & Technology.

Chess / Lichess.org
2300+Speed chess rating
Global Top 100Three-Check / 2026
Global Top 200Atomic Chess / 2020
Other certifications

Advanced Neurobiology I, Peking University · Derivatives—Options & Futures, Interactive Brokers · Innovate & Regulate: Drug Research, Davidson College · Google Cloud Artificial Intelligence